Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | inglese |
| Pubblicazione: |
2016
|
| Accesso online: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Lascia un commento!